Epithelioid peritoneal mesothelioma: A hybrid phenotype within a mesenchymal-epithelial/epithelial-mesenchymal transition framework

Fabio Bozzi, Silvia Brich, Gian Paolo Dagrada, Tiziana Negri, Elena Conca, Barbara Cortelazzi, Antonino Belfiore, Federica Perrone, Ambra Vittoria Gualeni, Annunziata Gloghini, Antonello Domenico Cabras, Monica Brenca, Roberta Maestro, Nadia Zaffaroni, Paolo Casali, Rossella Bertulli, Marcello Deraco, Silvana Pilotti

Research output: Contribution to journalArticle

Abstract

The aim of this study was to reconsider the biological characteristics of epithelioid malignant peritoneal mesothelioma (E-MpM) in the light of new concepts about epithelial mesenchymal transition and mesenchymal epithelial reverse transition (EMT/MErT) and the role of epigenetic reprogramming in this context. To this end we profiled surgical specimens and derived cells cultures by a number of complementary approaches i.e. immunohistochemistry, immunofluorescence, in situ hybridization, biochemistry, pluripotent stem cell arrays, treatments with cytokines, growth factors and specific inhibitors. The analyses of the surgical specimens showed that i) EZH2 is expressed throughout the spectrum of MpM, ii) that E-MpM (including the high-grade undifferentiated form) are characterised by c-MYC and miRNA 17-5p expression, and iii) that progression to sarcomatoid MpM is dictated by EMT regulators. They also showed that E-MpM expressed c-MET and are enriched in E- and P-cadherins- and VEGFR2-expressing CSCs, thus strongly supporting a role for MErT reprogramming in endowing E-MpM tumour cells with stemness and plasticity, and hence with a drug resistant phenotype. The cell culture-based experiments confirmed the stemness traits and plasticity of E-MpM, and support the view that EZH2 is a druggable target in this tumor.

Original languageEnglish
Pages (from-to)75503-75517
Number of pages15
JournalOncotarget
Volume7
Issue number46
DOIs
Publication statusPublished - 2016

Fingerprint

Epithelial-Mesenchymal Transition
Mesothelioma
Phenotype
Cell Culture Techniques
Pluripotent Stem Cells
Cadherins
MicroRNAs
Epigenomics
Biochemistry
In Situ Hybridization
Fluorescent Antibody Technique
Neoplasms
Intercellular Signaling Peptides and Proteins
Immunohistochemistry
Malignant Mesothelioma
Cytokines
Pharmaceutical Preparations

Keywords

  • Malignant peritoneal mesothelioma
  • MErT
  • MET

ASJC Scopus subject areas

  • Oncology

Cite this

Epithelioid peritoneal mesothelioma : A hybrid phenotype within a mesenchymal-epithelial/epithelial-mesenchymal transition framework. / Bozzi, Fabio; Brich, Silvia; Dagrada, Gian Paolo; Negri, Tiziana; Conca, Elena; Cortelazzi, Barbara; Belfiore, Antonino; Perrone, Federica; Gualeni, Ambra Vittoria; Gloghini, Annunziata; Cabras, Antonello Domenico; Brenca, Monica; Maestro, Roberta; Zaffaroni, Nadia; Casali, Paolo; Bertulli, Rossella; Deraco, Marcello; Pilotti, Silvana.

In: Oncotarget, Vol. 7, No. 46, 2016, p. 75503-75517.

Research output: Contribution to journalArticle

Bozzi, Fabio ; Brich, Silvia ; Dagrada, Gian Paolo ; Negri, Tiziana ; Conca, Elena ; Cortelazzi, Barbara ; Belfiore, Antonino ; Perrone, Federica ; Gualeni, Ambra Vittoria ; Gloghini, Annunziata ; Cabras, Antonello Domenico ; Brenca, Monica ; Maestro, Roberta ; Zaffaroni, Nadia ; Casali, Paolo ; Bertulli, Rossella ; Deraco, Marcello ; Pilotti, Silvana. / Epithelioid peritoneal mesothelioma : A hybrid phenotype within a mesenchymal-epithelial/epithelial-mesenchymal transition framework. In: Oncotarget. 2016 ; Vol. 7, No. 46. pp. 75503-75517.
@article{1b9b4564423a4f2bb3a51429c97bb832,
title = "Epithelioid peritoneal mesothelioma: A hybrid phenotype within a mesenchymal-epithelial/epithelial-mesenchymal transition framework",
abstract = "The aim of this study was to reconsider the biological characteristics of epithelioid malignant peritoneal mesothelioma (E-MpM) in the light of new concepts about epithelial mesenchymal transition and mesenchymal epithelial reverse transition (EMT/MErT) and the role of epigenetic reprogramming in this context. To this end we profiled surgical specimens and derived cells cultures by a number of complementary approaches i.e. immunohistochemistry, immunofluorescence, in situ hybridization, biochemistry, pluripotent stem cell arrays, treatments with cytokines, growth factors and specific inhibitors. The analyses of the surgical specimens showed that i) EZH2 is expressed throughout the spectrum of MpM, ii) that E-MpM (including the high-grade undifferentiated form) are characterised by c-MYC and miRNA 17-5p expression, and iii) that progression to sarcomatoid MpM is dictated by EMT regulators. They also showed that E-MpM expressed c-MET and are enriched in E- and P-cadherins- and VEGFR2-expressing CSCs, thus strongly supporting a role for MErT reprogramming in endowing E-MpM tumour cells with stemness and plasticity, and hence with a drug resistant phenotype. The cell culture-based experiments confirmed the stemness traits and plasticity of E-MpM, and support the view that EZH2 is a druggable target in this tumor.",
keywords = "Malignant peritoneal mesothelioma, MErT, MET",
author = "Fabio Bozzi and Silvia Brich and Dagrada, {Gian Paolo} and Tiziana Negri and Elena Conca and Barbara Cortelazzi and Antonino Belfiore and Federica Perrone and Gualeni, {Ambra Vittoria} and Annunziata Gloghini and Cabras, {Antonello Domenico} and Monica Brenca and Roberta Maestro and Nadia Zaffaroni and Paolo Casali and Rossella Bertulli and Marcello Deraco and Silvana Pilotti",
year = "2016",
doi = "10.18632/oncotarget.12262",
language = "English",
volume = "7",
pages = "75503--75517",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "46",

}

TY - JOUR

T1 - Epithelioid peritoneal mesothelioma

T2 - A hybrid phenotype within a mesenchymal-epithelial/epithelial-mesenchymal transition framework

AU - Bozzi, Fabio

AU - Brich, Silvia

AU - Dagrada, Gian Paolo

AU - Negri, Tiziana

AU - Conca, Elena

AU - Cortelazzi, Barbara

AU - Belfiore, Antonino

AU - Perrone, Federica

AU - Gualeni, Ambra Vittoria

AU - Gloghini, Annunziata

AU - Cabras, Antonello Domenico

AU - Brenca, Monica

AU - Maestro, Roberta

AU - Zaffaroni, Nadia

AU - Casali, Paolo

AU - Bertulli, Rossella

AU - Deraco, Marcello

AU - Pilotti, Silvana

PY - 2016

Y1 - 2016

N2 - The aim of this study was to reconsider the biological characteristics of epithelioid malignant peritoneal mesothelioma (E-MpM) in the light of new concepts about epithelial mesenchymal transition and mesenchymal epithelial reverse transition (EMT/MErT) and the role of epigenetic reprogramming in this context. To this end we profiled surgical specimens and derived cells cultures by a number of complementary approaches i.e. immunohistochemistry, immunofluorescence, in situ hybridization, biochemistry, pluripotent stem cell arrays, treatments with cytokines, growth factors and specific inhibitors. The analyses of the surgical specimens showed that i) EZH2 is expressed throughout the spectrum of MpM, ii) that E-MpM (including the high-grade undifferentiated form) are characterised by c-MYC and miRNA 17-5p expression, and iii) that progression to sarcomatoid MpM is dictated by EMT regulators. They also showed that E-MpM expressed c-MET and are enriched in E- and P-cadherins- and VEGFR2-expressing CSCs, thus strongly supporting a role for MErT reprogramming in endowing E-MpM tumour cells with stemness and plasticity, and hence with a drug resistant phenotype. The cell culture-based experiments confirmed the stemness traits and plasticity of E-MpM, and support the view that EZH2 is a druggable target in this tumor.

AB - The aim of this study was to reconsider the biological characteristics of epithelioid malignant peritoneal mesothelioma (E-MpM) in the light of new concepts about epithelial mesenchymal transition and mesenchymal epithelial reverse transition (EMT/MErT) and the role of epigenetic reprogramming in this context. To this end we profiled surgical specimens and derived cells cultures by a number of complementary approaches i.e. immunohistochemistry, immunofluorescence, in situ hybridization, biochemistry, pluripotent stem cell arrays, treatments with cytokines, growth factors and specific inhibitors. The analyses of the surgical specimens showed that i) EZH2 is expressed throughout the spectrum of MpM, ii) that E-MpM (including the high-grade undifferentiated form) are characterised by c-MYC and miRNA 17-5p expression, and iii) that progression to sarcomatoid MpM is dictated by EMT regulators. They also showed that E-MpM expressed c-MET and are enriched in E- and P-cadherins- and VEGFR2-expressing CSCs, thus strongly supporting a role for MErT reprogramming in endowing E-MpM tumour cells with stemness and plasticity, and hence with a drug resistant phenotype. The cell culture-based experiments confirmed the stemness traits and plasticity of E-MpM, and support the view that EZH2 is a druggable target in this tumor.

KW - Malignant peritoneal mesothelioma

KW - MErT

KW - MET

UR - http://www.scopus.com/inward/record.url?scp=84996773842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84996773842&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.12262

DO - 10.18632/oncotarget.12262

M3 - Article

AN - SCOPUS:84996773842

VL - 7

SP - 75503

EP - 75517

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 46

ER -